More Images
The COVID-19 booster vaccine typically causes transient, clinically insignificant elevations in glucose levels in people with type 1 diabetes, but some individuals may develop more pronounced hyperglycemia.

In a single-center prospective cohort study of 21 adults with type 1 diabetes, patients were given a blinded Dexcom G6 Pro continuous glucose monitor (CGM) at the first research clinic visit. After 3–4 days, participants received a COVID-19 booster vaccine.

They returned to the clinic 10 days after the initial visit (5–6 days after booster vaccination) to have the CGM removed and glycemia assessed. Compared to baseline, the mean daily glucose level was significantly increased at day 2 post vaccination.

"To our knowledge this is the first study investigating the effect of the COVID-19 booster vaccine on glycemia specifically in people with type 1 diabetes," said the authors of the study.

"Clinicians, pharmacists and other health care providers may need to counsel people with T1D to be more vigilant with glucose testing and insulin dosing for the first five days after vaccination. Most importantly, insulin, required to control glycemia, may need to be transiently increased.

"Further studies are warranted to investigate whether other vaccines have similar glycemic effects, and which individuals are at highest risk for profound glucose perturbations post-vaccination."

Head over to Medscape to read the full story.